6:50 PM · 15 December 2021

Vir Biotechnology stock surges on upbeat vaccine news

Vir Biotechnology (VIR.US) stock soars more than 14.0% after the drugmaker announced that recent data regarding its Covid-19 antibody therapy, which was developed in cooperation with GlaxoSmithKline (GSK.UK), showed positive effects against the omicron strain.

Vir Biotechnology (VIR.US) stock has been trading in a sideways move with some downside recently. However following positive news regarding the vaccine, stock launched today's session with a bullish price gap, nevertheless buyers failed to break above the upper limit of the consolidation zone around $54.15. As long as the price sits below, another downward impulse towards support at $34.30 may be launched. On the other hand, if bulls will manage to break above the aforementioned resistance, then upward move may accelerate towards $67.50, where March highs are located. Source: xStation5

20 August 2026, 7:56 AM

Morning Wrap: Asian Stocks in the Green, Bitcoin Rallies 8% – Has Risk Appetite Returned? (20.08.2026)

19 August 2026, 7:14 PM

Daily Summary: Bessent Shakes the Market – Dollar Down Sharply, Gold Up 3.5% (19.08.2026)

19 August 2026, 4:35 PM

US Open: Market Tries to Regain Ground, Moderna Up 140% (19.08.2026)

19 August 2026, 12:54 PM

Target shares fall despite strong results and guidance 🚩 Is the US consumer still holding up?

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits